银屑病患者的非酒精性脂肪性肝病纤维化评分
Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis.
作者信息
Gisondi P, Barba E, Girolomoni G
机构信息
Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
出版信息
J Eur Acad Dermatol Venereol. 2016 Feb;30(2):282-7. doi: 10.1111/jdv.13456. Epub 2015 Nov 4.
BACKGROUND
Patients with psoriasis are at risk of non-alcoholic fatty liver disease (NAFLD) and likely liver fibrosis.
OBJECTIVE
Investigate the prevalence of NAFLD in patients with psoriasis and measure their risk of liver fibrosis.
METHOD
One hundred and twenty-four patients with psoriasis and 79 healthy controls were included in this cross-sectional study. NAFLD was diagnosed in the presence of characteristic sonographic features of fatty liver after excluding other secondary causes of chronic liver disease. NAFLD fibrosis score (NAFLD-FS) was scored in those with NAFLD to measure the risk of advanced liver fibrosis.
RESULTS
Prevalence of NAFLD was greater in patients with psoriasis than in controls (44% vs. 26%, P < 0.001). NAFLD-FS was higher in patients with psoriasis than in controls, suggesting a higher risk of liver fibrosis in those with psoriasis (-1.57 ± 1.4 vs. -3.10 ± 1.5, mean ± SD, P < 0.0001). Psoriasis resulted in a significant predictor of advanced liver fibrosis independently of age, sex, BMI, hypertension and diabetes in the multivariate analysis.
CONCLUSIONS
Patients with psoriasis should be screened for common causes of liver disease, including NAFLD and liver fibrosis.
背景
银屑病患者存在非酒精性脂肪性肝病（NAFLD）及肝纤维化风险。
目的
调查银屑病患者中NAFLD的患病率，并评估其肝纤维化风险。
方法
本横断面研究纳入了124例银屑病患者和79例健康对照。排除其他慢性肝病的继发原因后，根据脂肪肝特征性超声表现诊断NAFLD。对NAFLD患者进行NAFLD纤维化评分（NAFLD-FS）以评估进展期肝纤维化风险。
结果
银屑病患者中NAFLD的患病率高于对照组（44%对26%，P<0.001）。银屑病患者的NAFLD-FS高于对照组，提示银屑病患者肝纤维化风险更高（-1.57±1.4对-3.10±1.5，均值±标准差，P<0.0001）。多因素分析显示，银屑病是进展期肝纤维化的显著预测因素，独立于年龄、性别、BMI、高血压和糖尿病。
结论
银屑病患者应筛查包括NAFLD和肝纤维化在内的常见肝病病因。
Zotero 插件